newsfilter
← Latest News
Business Wire·

VBI Vaccines Reports Third Quarter 2023 Financial Results

PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of